TL;DR: IRS Section 280E — which bars cannabis businesses from deducting ordinary business expenses — remains the single largest financial drag on U.S. cannabis operators, consuming an estimated $400–$600M in excess taxes annually. Recent Tax Court developments and the DEA’s Schedule III rescheduling proceedings are reshaping how operators model their post-transition financial profiles, with major implications for free cash flow at CURLF, GTBIF, VRNOF, and TCNNF.
Market Analysis: The 280E Burden by the Numbers
Section 280E of the Internal Revenue Code was enacted in 1982 following a Tax Court ruling that allowed a convicted cocaine dealer to deduct business expenses. The provision prohibits deductions for businesses trafficking in Schedule I or II controlled substances. For cannabis operators — classified under Schedule I — this has meant effective tax rates of 50–90% in profitable years, compared to the standard corporate rate of 21%.
Curaleaf Holdings (CURLF) disclosed approximately $38M in 280E-related tax payments on an annualized basis in its Q2 2026 filings, representing roughly 180 basis points of effective yield compression versus a standard corporate structure. Green Thumb Industries (GTBIF), while smaller by revenue, has consistently cited 280E as a primary factor limiting reported net income despite strong operational free cash flow generation. Track 280E-impacted names on the cannabis stock tracker.
Verano Holdings (VRNOF) and Trulieve Cannabis (TCNNF) face similar structural distortions. In TCNNF’s case, the company has employed an aggressive cost-of-goods allocation strategy to maximize deductible expenses under the limited provisions allowed by 280E — a practice that has drawn IRS scrutiny but remains legally defensible under current case law.
Regulatory Context: Schedule III and the 280E Escape Valve
The DEA’s pending rescheduling of cannabis from Schedule I to Schedule III is the most consequential near-term catalyst for the 280E issue. Schedule III substances are not subject to the trafficking prohibition in IRC Section 280E, which means finalized rescheduling would immediately make cannabis operators eligible to deduct standard business expenses: rent, salaries, marketing, interest on debt, and G&A costs.
The financial impact of 280E removal would be transformational. Analyst models suggest GTBIF, which reported $67M in net income on $1.03B in revenue in FY2025, could see net income expand by 40–60% on an all-else-equal basis post-280E removal. For CURLF, which has operated at marginal profitability due in part to the tax burden, 280E removal could be the catalyst that produces the company’s first GAAP-positive annual net income.
However, there is an important timing complexity equity investors may be underestimating. 280E’s inapplicability to Schedule III cannabis operators requires either congressional action amending the tax code or a definitive ruling that Schedule III-classified cannabis is no longer a trafficking substance under the statute. The IRS’s formal position on the effective date of any such change has not been published, creating uncertainty about whether operators could immediately begin expensing post-rescheduling or would need to wait for a clarifying revenue ruling or Treasury regulation.
What Operators Are Doing Now
The most sophisticated operators are not waiting passively for regulatory clarity. A consistent theme across Q2 2026 earnings calls was mention of financial architecture reviews — internal projects to model two balance sheet scenarios: (1) the current 280E-constrained structure and (2) a post-rescheduling structure with normalized tax treatment. These reviews have implications for capital allocation, debt refinancing strategy, and M&A activity.
Green Thumb Industries has been particularly proactive. The company’s Q2 2026 commentary indicated ongoing engagement with tax counsel around transition-period accounting, including questions about whether previously disallowed deductions could be recovered retroactively for tax years in which 280E was applied to what would retroactively become a Schedule III business. This retroactive recovery thesis — sometimes called 280E unwinding in analyst circles — remains highly uncertain legally but represents meaningful upside optionality.
Conclusion: 280E Is Priced In — But Not Optimally
The equity market’s current treatment of 280E removal as a when-not-if proposition is generally correct but imprecise on timing. Institutional models that assume 280E relief in H1 2027 may be ahead of themselves; models that ignore the catalyst entirely are leaving meaningful upside optionality off the table. The optimal analytical posture for October 2026 is to model the existing 280E-constrained structure as the baseline, with Schedule III rescheduling as a probability-weighted positive revision catalyst. Monitor all developments via the cannabis stock tracker and this publication’s ongoing coverage.